Eldrin F Lewis1, Brian L Claggett2, John J V McMurray2, Milton Packer2, Martin P Lefkowitz2, Jean L Rouleau2, Jiankang Liu2, Victor C Shi2, Michael R Zile2, Akshay S Desai2, Scott D Solomon2, Karl Swedberg2. 1. From the Brigham and Women's Hospital, Boston, MA (E.F.L., B.L.C., J.L., A.S.D., S.D.S.); BHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Novartis, East Hanover, NJ (M.P.L., V.C.S.); Institut de Cardiologie de Montreal, Université de Montreal, Canada (J.L.R.); Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston, SC (M.R.Z.); and Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden and National Heart and Lung Institute, Imperial College, London, United Kingdom (K.S.). eflewis@partners.org. 2. From the Brigham and Women's Hospital, Boston, MA (E.F.L., B.L.C., J.L., A.S.D., S.D.S.); BHF Cardiovascular Research Centre, University of Glasgow, United Kingdom (J.J.V.M.); Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX (M.P.); Novartis, East Hanover, NJ (M.P.L., V.C.S.); Institut de Cardiologie de Montreal, Université de Montreal, Canada (J.L.R.); Medical University of South Carolina and RHJ Department of Veterans Administration Medical Center, Charleston, SC (M.R.Z.); and Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden and National Heart and Lung Institute, Imperial College, London, United Kingdom (K.S.).
Abstract
BACKGROUND:Patients with heart failure and reduced ejection fraction have impaired health-related quality of life (HRQL) with variable responses to therapies that target mortality and heart failure hospitalizations. In PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced morbidity and mortality compared with enalapril. Another major treatment goal is to improve HRQL. Given improvements in mortality with sacubitril/valsartan, this analysis provides comprehensive assessment of impact of therapy on HRQL in survivors only. METHODS AND RESULTS: Patients (after run-in phase) completed disease-specific HRQL using Kansas City Cardiomyopathy Questionnaire (KCCQ) at randomization, 4 month, 8 month, and annual visits. Changes in KCCQ scores were calculated using repeated measures analysis of covariance model that adjusted for treatment and baseline values (principal efficacy prespecified at 8 months). Among the 8399 patients enrolled in PARADIGM-HF, 7623 (91%) completedKCCQ scores at randomization with complete data at 8 months for 6881 patients (90% of baseline). At 8 months, sacubitril/valsartan group noted improvements in both KCCQ clinical summary score (+0.64 versus -0.29; P=0.008) and KCCQ overall summary score (+1.13 versus -0.14; P<0.001) in comparison to enalapril group and significantly less proportion of patients with deterioration (≥5 points decrease) of both KCCQ scores (27% versus 31%; P=0.01). Adjusted change scores demonstrated consistent improvements in sacubitril/valsartan compared with enalapril through 36 months. CONCLUSIONS:Change scores in KCCQ clinical summary scores and KCCQ overall summary scores were better in patients treated with sacubitril/valsartan compared with those treated with enalapril, with consistency in most domains, and persist during follow-up beyond 8 months. These findings demonstrate that sacubitril/valsartan leads to better HRQL in surviving patients with heart failure. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.
RCT Entities:
BACKGROUND:Patients with heart failure and reduced ejection fraction have impaired health-related quality of life (HRQL) with variable responses to therapies that target mortality and heart failure hospitalizations. In PARADIGM-HF trial (Prospective Comparison of ARNI [Angiotensin Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortality and Morbidity in Heart Failure), sacubitril/valsartan reduced morbidity and mortality compared with enalapril. Another major treatment goal is to improve HRQL. Given improvements in mortality with sacubitril/valsartan, this analysis provides comprehensive assessment of impact of therapy on HRQL in survivors only. METHODS AND RESULTS:Patients (after run-in phase) completed disease-specific HRQL using Kansas City Cardiomyopathy Questionnaire (KCCQ) at randomization, 4 month, 8 month, and annual visits. Changes in KCCQ scores were calculated using repeated measures analysis of covariance model that adjusted for treatment and baseline values (principal efficacy prespecified at 8 months). Among the 8399 patients enrolled in PARADIGM-HF, 7623 (91%) completed KCCQ scores at randomization with complete data at 8 months for 6881 patients (90% of baseline). At 8 months, sacubitril/valsartan group noted improvements in both KCCQ clinical summary score (+0.64 versus -0.29; P=0.008) and KCCQ overall summary score (+1.13 versus -0.14; P<0.001) in comparison to enalapril group and significantly less proportion of patients with deterioration (≥5 points decrease) of both KCCQ scores (27% versus 31%; P=0.01). Adjusted change scores demonstrated consistent improvements in sacubitril/valsartan compared with enalapril through 36 months. CONCLUSIONS: Change scores in KCCQ clinical summary scores and KCCQ overall summary scores were better in patients treated with sacubitril/valsartan compared with those treated with enalapril, with consistency in most domains, and persist during follow-up beyond 8 months. These findings demonstrate that sacubitril/valsartan leads to better HRQL in surviving patients with heart failure. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01035255.
Authors: Anders Jorsal; Kasper Pryds; John J V McMurray; Henrik Wiggers; Anders Sommer; Jens Cosedis Nielsen; Roni Ranghøj Nielsen Journal: Clin Res Cardiol Date: 2019-09-26 Impact factor: 5.460
Authors: Muthiah Vaduganathan; Gregg C Fonarow; Stephen J Greene; Adam D DeVore; Nancy M Albert; Carol I Duffy; C Larry Hill; John A Spertus; Laine E Thomas; Javed Butler Journal: J Am Coll Cardiol Date: 2019-11-11 Impact factor: 24.094
Authors: Alvin Chandra; Eldrin F Lewis; Brian L Claggett; Akshay S Desai; Milton Packer; Michael R Zile; Karl Swedberg; Jean L Rouleau; Victor C Shi; Martin P Lefkowitz; Tzvetana Katova; John J V McMurray; Scott D Solomon Journal: JAMA Cardiol Date: 2018-06-01 Impact factor: 14.676
Authors: Yevgeniy Khariton; Gregg C Fonarow; Suzanne V Arnold; Ann Hellkamp; Michael E Nassif; Puza P Sharma; Javed Butler; Laine Thomas; Carol I Duffy; Adam D DeVore; Nancy M Albert; J Herbert Patterson; Fredonia B Williams; Kevin McCague; John A Spertus Journal: JACC Heart Fail Date: 2019-09-11 Impact factor: 12.035
Authors: Suleman Aktaa; Gorav Batra; Lars Wallentin; Colin Baigent; David Erlinge; Stefan James; Peter Ludman; Aldo P Maggioni; Susanna Price; Clive Weston; Barbara Casadei; Chris P Gale Journal: Eur Heart J Qual Care Clin Outcomes Date: 2022-01-05
Authors: José Manuel Rubio Campal; Hugo Del Castillo; Belén Arroyo Rivera; Carmen de Juan Bitriá; Mikel Taibo Urquia; Pepa Sánchez Borque; Ángel Miracle Blanco; Loreto Bravo Calero; David Martí Sánchez; José Tuñón Fernández Journal: Cardiol J Date: 2021-02-26 Impact factor: 2.737